Neurological disorder biotech Intra-Cellular Therapies files for a $115 million IPO

By Renaissance Capital,

Shutterstock photo

Intra-Cellular Therapies, a clinical-stage biotech developing treatments for neurological disorders, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The New York, NY-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol ITCI. It is currently traded on the OTC market under the same ticker. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ITCI

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by